March 8th 2024
Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
February 27th 2024
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cheson Considers the Most Effective Therapeutic Strategies for Patients With Follicular Lymphoma
March 27th 2018Bruce D. Cheson, MD, recently shared the treatment options and decisions he makes when treating patients with follicular lymphoma based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspective presentation.
Read More
EBRT Shows Promise in Relapsed/Refractory Follicular Lymphoma
March 16th 2018External beam radiation therapy can be effective when integrated in a multimodality treatment strategy for patients with relapsed/refractory follicular lymphoma, according to findings from a small, retrospective study.
Read More
Novel Gene Panel May Predict Response to Tazemetostat in NHL
March 16th 2018Tazemetostat showed efficacy in heavily treated patients with relapsed/refractory non-Hodgkin lymphoma in interim results from a phase II trial. Investigators hope that the analysis of a 62-gene panel biomarker performed on the same patient population will help to identify the patients who will have an even stronger response to the oral EZH2 inhibitor developed by Epizyme.
Read More
Results for the Combination of Nivolumab and Ibrutinib in Non-Hodgkin Lymphoma and CLL
March 14th 2018Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, discusses results from a trial studying the combination of nivolumab and ibrutinib for the treatment of patients with relapsed non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Watch
Using PET or CT for Staging Patients with Follicular Lymphoma
March 7th 2018Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, discusses current research for staging patients with follicular lymphoma. In order to design new clinical trials, researchers must have reliable predictors of overall survival and progression-free survival in patients.
Watch
A Look Back at FDA News in the Month of February
March 3rd 2018New indications were approved by the FDA within the last month, including abemaciclib for HER2-negative breast cancer, durvalumab for non–small cell lung cancer, and abiraterone acetate for castration-sensitive prostate cancer.
Read More
Umbralisib Shows Encouraging Early Activity in CLL and Lymphoma
February 23rd 2018According to phase I findings published in <em>The Lancet Oncology,</em> an objective response rate of 37% was induced in patients with relapsed/refractory lymphoma or chronic lymphocytic leukemia treated with the PI3K-delta inhibitor umbralisib.
Read More
Long-Term Follow-Up Results From the ZUMA-1 Trial in Non-Hodgkin Lymphoma
February 23rd 2018Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses long-term findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory aggressive non-Hodgkin lymphoma.
Watch
Liso-Cel Demonstrates "Remarkable" Activity, Lower Toxicity in Patients With DLBCL
February 22nd 2018Treatment with the CD19-targeted chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (liso-cel, formally known as JCAR017) demonstrated a complete response rate of 63% and an objective response rate of 81% in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Chemo/Radioimmunotherapy Treatment Strategy Induces 90% PFS at 3 Years in Follicular Lymphoma
February 16th 2018Combining consolidative radioimmunotherapy and sequential maintenance rituximab following chemoimmunotherapy improved progression-free survival at 3 years in patients with previously untreated follicular lymphoma, according to findings from the phase II SWOG S0801 study recently published in <em>The Lancet Hematology</em>.
Read More
Duvelisib Submitted for FDA Approval in CLL, Follicular Lymphoma
February 7th 2018Based on supporting data from the phase III DUO trial and the phase II DYNAMO study, duvelisib has been submitted to the FDA for a full approval for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma.
Read More
Andrew Evens Joins Rutgers Cancer Institute of New Jersey and RWJBarnabas Health
February 7th 2018Lymphoma expert Andrew M. Evens, DO, MSc, FACP, has joined Rutgers Cancer Institute of New Jersey as associate director. He is also serving as medical director of the oncology service line at RWJBarnabas Health. Evens will focus on integrated cancer care delivery in his roles across both institutions.
Read More
CHOP-RIT Regimen Improves PFS Over R-CHOP in Follicular Lymphoma
February 3rd 2018Progression-free survival was improved by nearly 15% with CHOP-RIT compared with R-CHOP alone in previously untreated patients with follicular lymphoma, according to findings from the phase III SWOG-S0016 trial published in the <em>Journal of Clinical Oncology</em>.
Read More
Rituximab Biosimilar Meets Endpoint in Phase III Follicular Lymphoma Trial
January 25th 2018Pfizer has announced that PF-05280586, a biosimilar for rituximab, has delivered positive top-line results, meeting its primary endpoint for overall response rate in the in the phase III REFLECTIONS B3281006 trial for patients with follicular lymphoma.
Read More
Expert Discusses Promising Efficacy of Oral Azacitidine in High-Risk Lymphoma
January 22nd 2018Peter Martin, MD, discusses a phase I, open-label, multicenter trial of oral azacitidine (Vidaza) plus R-CHOP in people with high-risk, previously untreated DLBCL, grade 3B follicular lymphoma, or transformed lymphoma.
Read More
Winter Stresses the Importance of Identifying Risk Status in Follicular Lymphoma Patients
January 18th 2018Jane N. Winter, MD, discusses recent updates in the field of follicular lymphoma, the importance of finding ways to identify patient populations, and challenges that still lie ahead.
Read More
Azacitidine Plus R-CHOP in High-Risk DLBCL
January 18th 2018Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a phase I, open-label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3B follicular lymphoma, or transformed lymphoma.
Watch